Showing 1701-1710 of 1870 results for "".
- Quick Eye Test May Flag Unrecognized Brain Injuryhttps://modernod.com/news/quick-eye-test-may-flag-unrecognized-brain-injury/2477145/A quick, noninvasive, handheld device that detects changes in pupil size may offer rapid assessment of potential brain injury in young athletes who have sustained a high-impact hit to the head but who exhibit no obvious signs of brain injury, according to a
- Ocugen Announces Completion of its Merger with Histogenics to Create Ocular Gene Therapies and Biotherapeuticshttps://modernod.com/news/ocugen-announces-completion-of-its-merger-with-histogenics-to-create-ocular-gene-therapies-and-biotherapeutics/2476924/Ocugen announced the completion of its merger with Histogenics, and the change of the combined company’s name to “Ocugen, Inc.” Ocugen is expected to begin trading today on The Nasdaq Capital Market under the ticker symbol “OCGN.” The executive team of Ocugen has become the executive team of the
- Carl Zeiss AG Names New President and CEOhttps://modernod.com/news/carl-zeiss-ag-names-new-president-and-ceo/2476913/At its meeting on September 24, the Supervisory Board of Carl Zeiss AG unanimously voted in favor of the following changes to the Executive Board: Dr. Karl Lamprecht, currently a member of the Executive Board, will become the new President & CEO effective April 1, 2020. Dr. Karl Lamprecht wil
- Eye Cancer Researchers at Bascom Palmer and Sylvester Identify Function of Key Tumor Suppressorhttps://modernod.com/news/eye-cancer-researchers-at-bascom-palmer-and-sylvester-identify-function-of-key-tumor-suppressor/2476900/Cancer cells remember things they shouldn’t. During development, stem and progenitor cells move freely through the body as they differentiate into heart, brain, liver, and eyes. But after humans are born, that process should stop. Cells shouldn’t travel or change anymore; they should stay put and
- Novartis Announces Details of TALON Global Clinical Trial in Wet AMD Comparing Brolucizumab vs Aflibercepthttps://modernod.com/news/novartis-announces-details-of-talon-global-clinical-trial-in-wet-amd-comparing-brolucizumab-vs-aflibercept/2476870/In the phase 3b TALON clinical trial, Novartis announced that the two primary endpoints are superiority for brolucizumab in treatment interval duration and noninferiority in change in visual acuity. Secondary endpoints will examine durability and anatomical outcomes, including retinal fluid resol
- New Research Suggests Glaucoma Screening Could Save Three Million Years Of Blindness In Chinahttps://modernod.com/news/new-research-suggests-glaucoma-screening-could-save-three-million-years-of-blindness-in-china/2476692/New research by Orbis International, Queen’s University Belfast, and Wenzhou Medical University has found that offering glaucoma screening in China could be highly cost-effective while reducing blindness among the population. The novel findings could change
- Verseon Showcases Oral Candidates for Next-Generation Diabetic Eye Disease Drugshttps://modernod.com/news/verseon-showcases-oral-candidates-for-next-generation-diabetic-eye-disease-drugs/2476626/Verseon presented a new class of oral candidate drugs which could change the treatment and prevention of diabetic macular edema (DME). “Our oral development candidate, a novel inhibitor of plasma kallikrein, has the potential to redefine how DME is treated,” Dr. Anirban Datta, Verse
- Ophtec Receives FDA Approval for RingJect Design Enhancementshttps://modernod.com/news/ophtec-receives-fda-approval-for-ringject-design-enhancements/2476536/Ophtec USA received FDA approval for the RingJect delivery system design optimization changes. Ophtec’s RingJect is a single use injector preloaded with the Ophtec Capsular Tension Ring (CTR). The Ophtec CTR is made of PMMA with patented compression molding technology, making for a durable
- Alcon Launches Project Presbyopia to Educate Eye Care Providers and Consumers During Presbyopia Awareness Monthhttps://modernod.com/news/alcon-launches-project-presbyopia-to-educate-eye-care-providers-and-consumers-during-presbyopia-awareness-month/2476460/Alcon is launching Project Presbyopia as part of Presbyopia Awareness Month in April. Project Presbyopia is an ongoing effort to educate consumers about how to recognize signs and symptoms of vision changes, uncover more intuitive language for the condition, and drive existing and emerging presby
- Johnson & Johnson Vision Announces Availability of Acuvue Oasys With Transitions Light Intelligent Technology in the U.S.https://modernod.com/news/johnson-johnson-vision-announces-availability-of-acuvue-oasys-with-transitions-light-intelligent-technology-in-the-u-s/2479584/Johnson & Johnson Vision announced the US availability of Acuvue Oasys with Transitions Light Intelligent Technology. The contact lenses adapt to changing light, helping eyes recover from bright light up to 5 seconds faster, reducing halos and starbursts at night, and delivering more sight w